TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Avanir Pharmaceuticals Inc (NASDAQ:AVNR) Investor Investigation Over Potential Securities Laws Violations

  • If you purchased shares of Avanir Pharmaceuticals Inc (NASDAQ:AVNR), you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Investigation Overview

December 17, 2013 (Update) -- On December 10, 2013, Avanir Pharmaceuticals Inc reported financial results for the three and twelve-months ended September 30, 2013 and announced results for phase II PRIME Study. Avanir Pharmaceuticals said that PRIME, its phase II clinical trial of the investigational drug AVP-923 (dextromethorphan / quinidine) for the treatment of central neuropathic ...



You must register (for free) or login to view the entire investigation.

Click here to Sign In or Register (for a free account)

@screen width:
@theme:
@breakpoints:
@layout: